HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Q3 Consumer Health Earnings Preview: Coming Changes Overshadow Current Conditions?

Executive Summary

Rather than reflecting what’s coming in the way of spinoffs, leadership, product approvals or deal closings, firms’ July-September results will reveal influences from inflation and supply chain problems. Like manufacturers across industries, US consumer health product firms are dealing with US currency strengthening and potentially driving down revenues through losses in foreign exchange.

You may also be interested in...



Strongest US Cough/Cold Season In 10 Years Likely

Increasing numbers cough/cold drug prescriptions combined with consumers’ waning interest in flu vaccines point to 2022-2023 season rivaling decade-high levels from 2017-18 and to retailers boosting inventories through year-end, Raymond James analysts say.

Londoners Get J&J Brands 'In Minutes' 24/7 Via Zapp Partnership

Johnson & Johnson's OTC brands including Benadryl, Benylin, Calpol, Imodium, Nicorette and Sudafed, as well as its personal care brands such as Aveeno and Neutrogena, are now available for home delivery 24/7 via the Zapp app to consumers in London, UK.

Branding For J&J’s Kenvue Cements Consumer Division Separation

In advance of spinning off its consumer division in 2023, Johnson & Johnson has announced the new standalone company will be called Kenvue.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

RS153013

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel